Gsa Capital Partners LLP Cidara Therapeutics, Inc. Transaction History
Gsa Capital Partners LLP
- $1.19 Billion
- Q1 2024
A detailed history of Gsa Capital Partners LLP transactions in Cidara Therapeutics, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 456,606 shares of CDTX stock, worth $5.12 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
456,606
Previous 540,446
15.51%
Holding current value
$5.12 Million
Previous $426,000
1.41%
% of portfolio
0.04%
Previous 0.04%
Shares
7 transactions
Others Institutions Holding CDTX
# of Institutions
53Shares Held
22.2MCall Options Held
2.7KPut Options Held
100-
Bvf Inc San Francisco, CA6.86MShares$76.9 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.35MShares$37.5 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.55MShares$28.6 Million0.0% of portfolio
-
Alethea Capital Management, LLC San Diego, CA1.6MShares$17.9 Million1.21% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.25MShares$14 Million0.0% of portfolio
About Cidara Therapeutics, Inc.
- Ticker CDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,075,696
- Market Cap $786M
- Description
- Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...